Table 3.
Treatment status
| Treatment status | Use following csDMARD-IR (first-line biologic agent) | Use following first bDMARD-IR (second-line biologic agent) | ||||
|---|---|---|---|---|---|---|
| Abatacept | TNFi | p value | Abatacept | TNFi | p value | |
| n | 92 | 613 | – | 105 | 212 | – |
| Stopped treatment, n (%) | 47 (51.1) | 365 (59.5) | 0.1404 | 60 (57.1) | 157 (74.1) | 0.0031 |
| Treatment duration, years, mean (SD) | 1.57 (1.68) | 2.01 (2.23) | 0.1068 | 1.76 (1.78) | 1.33 (1.70) | 0.1045 |
| Reasons for stopping, n (%) | 0.1351 | 0.4409 | ||||
| Inefficacy | 28 (59.6) | 171 (46.8) | 38 (63.3) | 86 (54.8) | ||
| Adverse event | 8 (17.0) | 76 (20.8) | 12 (20.0) | 27 (17.2) | ||
| Lost to follow-up | 2 (4.3) | 21 (5.8) | 0 | 6 (3.8) | ||
| Treatment stopped by the patient | 3 (6.4) | 14 (3.8) | 0 | 4 (2.5) | ||
| Infections | 3 (6.4) | 22 (6.0) | 2 (3.3) | 9 (5.7) | ||
| Death | 0 | 7 (1.9) | 3 (5.0) | 4 (2.5) | ||
| Ongoing treatment | 45 (48.9) | 248 (40.5) | 0.1404 | 45 (42.9) | 55 (25.9) | 0.0031 |
| Treatment duration, years, mean (SD) | 4.46 (2.99) | 6.25 (3.25) | 0.0007 | 4.57 (2.69) | 4.15 (2.68) | 0.4364 |
bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR inadequate response, TNFi tumor necrosis factor inhibitor